Cost-effectiveness of Interferon Alfa-2b With and Without Ribavirin as Therapy for Chronic Hepatitis C in Sweden

References

• Alter M, Kruszon-Moran D, Nainan O, McQuillan G, Gao F, Moyer L, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341: 556–62.
   PubMed Web of Science ®Google Scholar
• Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32 Suppl 1:98–112.
   PubMedGoogle Scholar
• Socialstyrelsen, Hälso-och sjukvårdsstatistisk årsbok 1999. 1999; Stockholm: Socialstyrelsen.
   Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72.
   PubMed Web of Science ®Google Scholar
• El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–50.
   Google Scholar
• Tong M, el-Farra N, Reikes A, Co R. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332: 1463–6.
   Google Scholar
• Liang TJ. Combination therapy for hepatitis C infection. N Engl J Med 1998;339:1549–50.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A. Liver transplantation for hepatitis C: the promise and the challenge. Hepatology 1995;22:660–2.
   PubMedGoogle Scholar
• Samuel D, Feray C. Recurrence of hepatitis C virus infection after liver transplantation. J Hepatol 1999;31 Suppl 1:217–21.
   PubMedGoogle Scholar
• Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. The Lancet 1998;352:1426–32.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–92.
   PubMed Web of Science ®Google Scholar
• Reichard O, Norkrans G, Fryden A, Braconier J, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83–7.
   PubMed Web of Science ®Google Scholar
• Wong J, Poynard T, Ling M-H, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis. Am J Gastroenterol 2000;95: 1524–30.
   Google Scholar
• Bennett WG, Inoue Y, Beck R, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855–65.
   PubMed Web of Science ®Google Scholar
• Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687–95.
   PubMed Web of Science ®Google Scholar
• Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero M, et al. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis C. J Hepatol 1992;16:273–81.
   PubMed Web of Science ®Google Scholar
• Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993;88:514–9.
   PubMed Web of Science ®Google Scholar
• Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: results of a randomized, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Scleratherapy Group. Hepatology 1994;20:618–25.
   Google Scholar
• Christensen E, Krintel J, Hansen S, Johansen J, Juhl E. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors. Scand J Gastroenterol 1989;24:999–1006.
   Google Scholar
• Graffeo M, Buffoli F, Lanzani G, Donato F, Benedini D, Rolfi F, et al. Survival after endoscopic sclerotherapy for esophageal varices in cirrhotics. Am J Gastroenterol 1994;89:1815–22.
   PubMedGoogle Scholar
• Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240–3.
   PubMed Web of Science ®Google Scholar
• Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675–80.
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797–801.
   PubMed Web of Science ®Google Scholar
• Gane E, Portmann B, Naoumov N, Smith H, Underhill J, Donaldson P, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815–20.
   PubMed Web of Science ®Google Scholar
• Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334–40.
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russel L, Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Sennfält K, Magnusson M, Carlsson P. Comparison of treatments of chronic kidney failure, with focus on hemo dialysis and peritoneal dialysis: a cost-utility analysis [Abstract]. European Health Management Association. 2000. Örebro, Sweden.
   Google Scholar
• Sarasin F, Gaspoz J, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000;160:2773–8.
   Google Scholar